MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - mnc pharma
- SANOFI INDIA - ADCOCK INGRAM (S. Africa)
SANOFI INDIA vs ADCOCK INGRAM (S. Africa) - Comparison Results
SANOFI INDIA Change
Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More
ADCOCK INGRAM (S. Africa)
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
Financials
 SANOFI INDIA  ADCOCK INGRAM |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| SANOFI INDIA Dec-18 |
ADCOCK INGRAM Jun-14 |
SANOFI INDIA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 6,840 | 376 | - | |
| Low | Rs | 4,630 | 271 | - | |
| Sales per share (Unadj.) | Rs | 1,203.1 | 111.7 | - | |
| Earnings per share (Unadj.) | Rs | 165.3 | -28.1 | - | |
| Cash flow per share (Unadj.) | Rs | 209.9 | -23.3 | - | |
| Dividends per share (Unadj.) | Rs | 84.00 | 0 | - | |
| Dividend yield (eoy) | % | 1.5 | 0 | - | |
| Book value per share (Unadj.) | Rs | 963.6 | 87.7 | - | |
| Shares outstanding (eoy) | m | 23.03 | 168.78 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.8 | 2.9 | 164.7% | |
| Avg P/E ratio | x | 34.7 | -11.5 | -302.2% | |
| P/CF ratio (eoy) | x | 27.3 | -13.9 | -197.2% | |
| Price / Book Value ratio | x | 6.0 | 3.7 | 161.5% | |
| Dividend payout | % | 50.8 | 0 | - | |
| Avg Mkt Cap | Rs m | 132,078 | 54,555 | 242.1% | |
| No. of employees | `000 | 3.3 | 4.3 | 76.9% | |
| Total wages/salary | Rs m | 4,068 | 3,424 | 118.8% | |
| Avg. sales/employee | Rs Th | 8,393.8 | 4,392.1 | 191.1% | |
| Avg. wages/employee | Rs Th | 1,232.4 | 797.6 | 154.5% | |
| Avg. net profit/employee | Rs Th | 1,153.0 | -1,106.7 | -104.2% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 27,708 | 18,855 | 147.0% | |
| Other income | Rs m | 897 | 132 | 679.3% | |
| Total revenues | Rs m | 28,605 | 18,987 | 150.7% | |
| Gross profit | Rs m | 6,235 | -3,267 | -190.8% | |
| Depreciation | Rs m | 1,027 | 814 | 126.2% | |
| Interest | Rs m | 7 | 511 | 1.4% | |
| Profit before tax | Rs m | 6,098 | -4,460 | -136.7% | |
| Minority Interest | Rs m | 0 | -12 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 2,292 | 279 | 822.4% | |
| Profit after tax | Rs m | 3,806 | -4,751 | -80.1% | |
| Gross profit margin | % | 22.5 | -17.3 | -129.9% | |
| Effective tax rate | % | 37.6 | -6.2 | -601.5% | |
| Net profit margin | % | 13.7 | -25.2 | -54.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 15,922 | 13,810 | 115.3% | |
| Current liabilities | Rs m | 6,235 | 7,770 | 80.2% | |
| Net working cap to sales | % | 35.0 | 32.0 | 109.1% | |
| Current ratio | x | 2.6 | 1.8 | 143.7% | |
| Inventory Days | Days | 64 | 111 | 57.4% | |
| Debtors Days | Days | 21 | 124 | 16.8% | |
| Net fixed assets | Rs m | 7,539 | 8,050 | 93.7% | |
| Share capital | Rs m | 230 | 88 | 262.7% | |
| Net worth | Rs m | 22,192 | 14,799 | 150.0% | |
| Long term debt | Rs m | 0 | 5,201 | 0.0% | |
| Total assets | Rs m | 29,839 | 27,957 | 106.7% | |
| Interest coverage | x | 872.1 | -7.7 | -11,279.3% | |
| Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
| Sales to assets ratio | x | 0.9 | 0.7 | 137.7% | |
| Return on assets | % | 12.8 | -15.2 | -84.3% | |
| Return on equity | % | 17.2 | -32.1 | -53.4% | |
| Return on capital | % | 27.5 | -19.8 | -138.9% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 3,739 | 1,609 | 232.3% | |
| From Investments | Rs m | -731 | -494 | 147.9% | |
| From Financial Activity | Rs m | -1,972 | 4,720 | -41.8% | |
| Net Cashflow | Rs m | 1,036 | 5,835 | 17.8% | |
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.18 Rs / ZAR
Compare SANOFI INDIA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare SANOFI INDIA With: AUROBINDO PHARMA VENUS REMEDIES DR. REDDYS LAB DR. DATSONS LABS DISHMAN PHARMA
Today's Market
Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)
Indian share markets witnessed positive trading activity throughout the day today and ended higher.
Related Views On News
SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)
Oct 29, 2020 | Updated on Oct 29, 2020For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)
Aug 26, 2020 | Updated on Aug 26, 2020For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
Why Did Alembic Pharma Shares Fall Today? (Views On News)
May 5, 2021Covid-led supply disruptions of API fuel Alembic Pharma's global prospects.
More Views on NewsMost Popular
Time to Buy Smallcaps? (Fast Profits Daily)
Apr 30, 2021In this video, I'll show you why I favour smallcaps over the Nifty.
The Next Smallcap Winners (Profit Hunter)
Apr 30, 2021Price is the only due diligence one might require to buy this business.
Sell in May and Go Away? (Fast Profits Daily)
Apr 28, 2021Does the concept of selling stocks in the month of May, work in the Indian market?
This Fund Manager Has Taken the World by Storm. Will You Invest With Her? (Profit Hunter)
Apr 26, 2021Should you invest with this Rockstar fund manager who has outperformed in a big way?
More
